“In terms of vaccines and therapies, as a reminder, we said we would expect to do in our core revenue about $1.5 billion this year. We did just under $400 million in Q3. That brings the year-to-date to $1.3 billion and on track to achieve or exceed the $1.5 billion.”

How to check this claim

Look at: Core COVID-19 vaccines and therapies revenue, full fiscal year 2022

It came true if: Full-year 2022 core vaccines/therapies revenue >= $1.5 billion

Where: Company quarterly/annual earnings release or 10-K disclosure of COVID-19 vaccines and therapies revenue (Thermo Fisher Scientific)

Verify independently

SEC filings for TMO ↗ · Claim quote is verbatim from the 2022Q3 earnings call.